Progression-free survival estimation of docetaxel-based second-line treatment for advanced non-small cell lung cancer: a pooled analysis from 18 randomized control trials

BackgroundLung cancer is the foremost cause of cancer-related death globally, with non-small cell lung cancer (NSCLC) accounting for 85–90% of cases. Targeted therapy is the most essential therapeutic option for NSCLC, other common treatments include radiation therapy, surgery, chemotherapy, and imm...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Chaithra N, Anisha Jain, Sahana C, Bhargav Shreevatsa, Saravanan Rajendrasozhan, Chandan Dharmashekar, Kuralayanapalya Puttahonnappa Suresh, Sharanagouda S. Patil, Pranav Singh, Prashant Vishwanath, Chandrashekar Srinivasa, Shiva Prasad Kollur, Chandan Shivamallu
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2024-05-01
coleção:	Frontiers in Oncology
Assuntos:	non-small cell lung carcinoma lung neoplasms progression-free survival randomized control trials meta analysis
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1298786/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!